|
Alexion Antibody Technologies |
|
|
3985 Sorrento Valley Blvd., Ste. A
San Diego, CA 92121 USA
phone:(858) 550-3490
fax:(858) 550-3498
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.alxnsd.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Antibody therapeutics targeting severe unmet medical needs. |
|
| Management |
| Katherine S. Bowdish, Ph.D., President |
| |
|
|
| |
|
| Keywords |
| antibody, cancer, autoimmune disorder, infectious disease, chemotherapy-induced thrombocytopenia, InfectiousDisease |
|
|
|
| Description |
|
AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting severe unmet medical needs. |
|
| Products / Services |
Alexion is developing a rationally design antibody-based therapeutic for the treatment of chemotherapy-induced thrombocytopenia. Alexion's compound employs an antibody structure that incorporates an active peptide genetically inserted into the antibody. The active peptide replaces a region of the antibody that is important for the binding properties of the antibody.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members